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Highly active antiretroviral therapy (HAART) can reduce plasma HIV-1 levels to below the detection limit.
However, due to the latent reservoir in resting CD4 cells, HAART is not curative. Elimination of this reservoir is
critical to curing HIV-1 infection. Agents that reactivate latent HIV-1 through nonspecific T cell activation are toxic.
Here we demonstrate in a primary CD4 T cell model that the FDA-approved drug disulfiram reactivates latent
HIV-1 without global T cell activation. The extent to which disulfiram reactivates latent HIV-1 in patient cells is
unclear, but the drug alone or in combination may be useful in future eradication strategies.
Highly active antiretroviral therapy (HAART) can reduce
plasma HIV-1 levels to below the detection limit of clinical
assays and reverse disease progression. However, HIV-1 per-
sists in latently infected resting CD4 T cells carrying an inte-
grated HIV-1 genome (3). In these cells, the provirus remains
transcriptionally silent as long as the host cell remains quies-
cent, allowing evasion of immune surveillance as well as of
HAART, which targets replicating viruses (4, 7, 16). Following
cellular activation, latent viral genomes are transcribed and
virus is produced, contributing to rebound viremia upon dis-
continuation of HAART. The estimated size of this latent
reservoir is 105 to 106 cells/patient, and the estimated half-life
is 44 months (12), resulting in an elimination time of 60
years. This stable reservoir makes life-long HAART necessary.
Given the potentials for toxicity and resistance and the expense
of HAART, elimination of the latent reservoir is an important
goal (14).
The reactivation of latent HIV-1 in patients on HAART is
an approach for elimination of the latent reservoir (2, 5, 14). It
is assumed that following reactivation infected cells will die
from viral cytopathic effects or host cytolytic mechanisms. If
this assumption is incorrect, reactivation strategies must be
coupled with strategies that kill productively infected cells (2).
In any event, the first step is to reactivate HIV-1 gene expres-
sion. We developed a primary cell model of HIV-1 latency to
search for compounds that reverse latency. Primary human
CD4 T cells were transduced with the prosurvival gene bcl-2
to allow long-term in vitro culture. Latency was established by
infecting transduced CD4 lymphoblasts and allowing them to
return to a resting state that recapitulated the state of resting
CD4 T cells in vivo (17). The virus used contains destabilized
green fluorescent protein (GFP) in the env open reading
frame, allowing detection of virus gene expression. Using this
system, we screened the Johns Hopkins Drug Library and the
MicroSource Spectrum Library (Fig. 1) and identified 8 hits in
addition to the previously described hit 5-hydroxynaphthoqui-
none (17). Of these, 6 were confirmed with fresh drug samples.
One of the confirmed hits, disulfiram, is an FDA-approved
drug.
Disulfiram [bis(diethylthiocarbamoyl) disulfide] is used to
treat alcoholism. It inhibits aldehyde dehydrogenase, leading
to increased acetaldehyde levels in patients who drink alcohol
while on disulfiram. Acetaldehyde has aversive effects that
deter alcohol consumption. Disulfiram chelates copper (13)
and inhibits the copper-containing enzyme dopamine -hy-
droxylase (DH) (15). Disulfiram also inhibits plasma carbox-
ylesterases and cholinesterase, blocking cocaine and dopamine
metabolism. Increased blood levels of these compounds lead to
unpleasant anxiety, making disulfiram useful in treating co-
caine dependence (10). Disulfiram has little toxicity in the
absence of alcohol or cocaine, and it is used to treat both these
addictions in HIV-1-infected individuals. Disulfiram also in-
hibits angiogenesis (11).
We examined the dose-response relationship and the kinet-
ics of disulfiram reactivation of latent HIV-1 by using latently
infected, Bcl-2-transduced CD4 T cells. Latently infected
cells were treated with serial dilutions of disulfiram for various
times, and reactivation was measured by flow cytometry as the
percentage of GFP cells, normalized to the percentage of
GFP cells following costimulation with anti-CD3 plus anti-
CD28 antibodies. Cells from different donors showed similar
dose-response curves (Fig. 2A). For most donors, peak activa-
tion occurred at 0.3 M, below the reported peak plasma
concentration of disulfiram (1.4 M) (6).
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The dose-response curves for HIV-1 reactivation by disul-
firam have two peaks. The first peak appears around 0.3 to 0.5
M disulfiram, and the second appears around 5 to 10 M.
The decrease in GFP cells over the range of 0.5 to 2 M may
reflect activation of inhibitory pathways. The first peak decays
with time, showing much lower reactivation after 48 h. The
second peak appears later than the first (24 h versus 6 h) and
does not decay (Fig. 2B). The kinetic differences between the
peaks indicate that multiple mechanisms may be involved in
the reactivation of latent HIV-1 by disulfiram.
To confirm the effect of disulfiram on latent HIV-1, we
examined levels of HIV-1 transcripts before and after disul-
firam stimulation. Multiply spliced transcripts encoding Tat
and full-length HIV-1 transcripts were measured. Latently in-
fected Bcl-2-transduced cells were treated for various times
with 0.5 or 5 M disulfiram or with anti-CD3 plus anti-CD28
antibodies or were left untreated. Total RNA was isolated
using RNeasy (Qiagen). Reverse transcription was performed
using SuperScript III reverse transcriptase (RT; Invitrogen)
with random hexamers, and transcript levels were measured by
FIG. 1. Screening of small-molecule libraries identifies disulfiram as an agent that reactivates latent HIV-1. (A) Summary of screening results
from the MicroSource Spectrum library. The results were normalized to the response to 10 ng/ml phorbol myristate acetate. (B) Chemical
structures of disulfiram and its metabolites, DDTC and DDTC-Me. (C) Representative flow cytometry data sets for untreated, disulfiram-treated,
and anti-CD3 plus anti-CD28 antibody-treated cells. The dot plots in the first row are forward scatter-side scatter (FSC-SSC) plots. Histographs
in the second row show cells gated in R1 in FSC-SSC plots. The GFP-FL2 dot plots in the third row show viable cells gated in R2 in propidium
iodide histographs. Cells that appear in R3 (GFP) are reactivated latently infected cells. The percentage of GFP cells was calculated based on
the number of cells in R3 divided by the number of cells in R2.
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real-time RT-PCR with SYBR Green PCR master mix (Ap-
plied Biosystems). Results were normalized to 18S rRNA. At
16 h, 0.5 M disulfiram increased Tat transcripts by 6-fold
and full-length transcripts by 4-fold relative to untreated
samples (Fig. 2C). The increase in HIV-1 transcripts was lower
with 5 M disulfiram, consistent with the lower reactivation
levels observed by fluorescence-activated cell sorting. We also
observed a time dependence of transcriptional induction by 0.5
M disulfiram (Fig. 2D). The induction of multiply spliced Tat
transcripts was observed as early as 2 h after treatment, fol-
lowed by the full-length transcripts. The induction increased
with time during the first 8 h, then fell to initial transcript levels
at 24 h. This may have caused the lower percentage of GFP
cells at 48 h. Together these results show that disulfiram in-
creases HIV-1 gene expression in latently infected cells in this
primary cell model.
In this system, peak GFP expression occurred 24 h postac-
tivation, with the number of GFP cells approaching 50% of
that seen with anti-CD3 plus anti-CD28 treatment (Fig. 2B).
FIG. 3. Disulfiram does not cause CD4 T cell activation. (A) Ef-
fects of disulfiram and anti-CD3 plus anti-CD28 treatment on the sizes
of resting CD4 T cells. Cell size was measured by flow cytometry
based on forward scatter at 24 h and 48 h. (B) Effects of disulfiram and
DDTC on the expression of activation markers in primary resting
CD4 T cells, compared to the effect of anti-CD3 plus anti-CD28
costimulation. Data are means plus standard deviations of triplicate
samples from 1 of 2 independent experiments. (C) Effects of disulfiram
and DDTC on global DNA and RNA levels in primary resting CD4
T cells, compared to the effect of anti-CD3 plus anti-CD28 costimu-
lation. Hoechst 33342 and pyronin Y were used to stain DNA and
RNA, respectively, and results were read using a flow cytometer.
FIG. 2. (A) Effects of disulfiram on latently infected Bcl-2-trans-
duced CD4 T cells from different donors. (B) Kinetic profile for the
reactivation of latent HIV-1 by different concentrations of disulfiram.
(C) Effects of disulfiram and costimulation on levels of HIV-1 tran-
scripts in latently infected Bcl-2-transduced cells after 16 h of treat-
ment. The fold change is shown relative to levels in untreated cells.
Data are means plus standard deviations of triplicate samples from 1
of 2 independent experiments, both of which produced similar results.
(D) Kinetic profile of the effect of 0.5 M disulfiram on levels of
HIV-1 transcripts in latently infected Bcl-2-transduced cells. The fold
change is shown relative to levels in untreated cells. Data are means
plus standard deviations of triplicate samples from 1 of 2 independent
experiments, both of which produced similar results. (E) Comparison
of disulfiram, DDTC, and DDTC-Me for reactivating latent HIV-1.
(F) Toxicity of disulfiram and DDTC treatment, measured in a pro-
pidium iodide exclusion assay.
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Although disulfiram cannot reactivate the entire latent reser-
voir in a single treatment, higher efficiency can be achieved by
multiple rounds of treatment. After treating the latently in-
fected cells with 0.5 M disulfiram, we sorted GFP cells and
treated them again with 0.5 M disulfiram, and we observed
GFP cells at a level that was 35% of similarly treated cultures
activated with anti-CD3 plus anti-CD28 (data not shown).
In vivo, disulfiram is rapidly converted to diethyldithiocar-
bamic acid (DDTC) (Fig. 1B) (8). In our system, DDTC also
reactivates latent HIV-1 (Fig. 2E; see also Fig. S1 in the sup-
plemental material). However, the next metabolite, diethyldi-
thiocarbamate methyl ester (DDTC-Me), does not reactive
latent HIV-1, suggesting that the free thiol is critical for reac-
tivation. In plasma, disulfiram is 95% protein bound (8). To
assess the effects of protein binding, reactivation experiments
were carried out in 50% human serum. The dose-response
curves for reactivation of latent HIV-1 shifted to the right by
10-fold (data not shown). Neither disulfiram nor DDTC
caused significant toxicity below 10 M (Fig. 2F).
Since agents that induce latent HIV-1 through global T cell
activation are toxic, we confirmed that disulfiram does not
cause global T cell activation. Increased cell size is a direct
indicator of T cell activation. Unlike cells stimulated with anti-
CD3 plus anti-CD28 antibodies, latently infected cells treated
with disulfiram retained the same small size as untreated cells
(Fig. 3A). By staining for well-characterized activation mark-
ers, we confirmed that neither disulfiram nor DDTC induced T
cell activation. Freshly isolated primary resting CD4 T cells
were treated with different concentrations of disulfiram,
DDTC, or anti-CD3 plus anti-CD28 for 24 h and then stained
for surface expression of CD69, CD25, and HLA-DR. Neither
disulfiram nor DDTC upregulated surface expression of these
markers, except for a minor induction of CD69 (Fig. 3B). In
addition, no change was observed in surface expression of
CCR7 (data not shown). Neither disulfiram nor DDTC in-
duced changes in global DNA or RNA levels as measured by
Hoechst 33342/pyronin Y staining, indicating that disulfiram
treatment does not stimulate proliferation in primary resting
CD4 T cells (Fig. 3C).
Clinical toxicity caused by global T cell activation is most
likely due to cytokine release. Therefore, we determined
whether disulfiram induces production of cytokines by using
real-time RT-PCR and cytokine arrays. Freshly isolated pri-
mary resting CD4 T cells were treated for 24 h with disul-
firam, DDTC, or anti-CD3 plus anti-CD28 antibodies or were
left untreated. Total RNA was isolated and reverse transcribed
as described above. Gamma interferon (IFN-), interleukin-2
(IL-2), and tumor necrosis factor alpha (TNF-) transcripts
were measured in TaqMan gene expression assays. Results
were normalized to 18S rRNA. None of the three cyto-
kines were induced by disulfiram or DDTC (Table 1). In ad-
dition, cytokine secretion by primary resting CD4 T cells
treated with medium alone, disulfiram, or DDTC or costimu-
lated for 48 h was measured using the Meso Scale human
TH1/TH2 10-plex cytokine array. Neither disulfiram nor
DDTC induced significant cytokine secretion compared to co-
stimulation (Table 1).
To gain insight into the potential clinical efficacy of disul-
firam, we measured virus release by primary resting CD4 T
cells from patients on suppressive HAART following disul-
firam stimulation. Levels of HIV-1 RNA in the supernatants of
disulfiram-treated cells were low compared to those seen with
costimulation (see Table S1 in the supplemental material). In
addition, a previously described virus culture assay (1) was
used to determine whether disulfiram induced release of rep-
lication-competent virus from CD4 T cells of patients on
suppressive HAART. Disulfiram-induced virus production was
not detected (data not shown). These in vitro results could
reflect additional mechanisms that enforce latency in vivo but
which were not captured in our primary cell model. Alterna-
tively, disulfiram may upregulate virus gene expression in pa-
tient cells, but restrictions on virus assembly and/or budding
may interfere with detection of this reactivation. Disulfiram-
treated resting CD4 T cells remain quiescent and are thus
fundamentally different than cells activated by costimulation.
The limitations inherent in in vitro assays with patient cells
suggest that in vivo studies in macaque models or in patients
will be required to determine the efficacy of latency-reversing
drugs like disulfiram.
In conclusion, disulfiram can induce HIV-1 gene expression
in latently infected cells in a primary cell model without caus-
ing a substantial degree of T cell activation. This work expands
TABLE 1. Cytokine profiles of in vitro-stimulated primary human resting CD4 T cells
Cytokine



















TNF- 0.0 0.8 	 0.0 1.4 	 0.1 0.8 	 0.2 1.5 	 0.1 12,814.7 	 300.9 0.7 	 0.3 1.1 	 0.2 148.0 	 3.5
IFN- 0.0 0.0 0.0 0.0 0.0 15,765.4 	 839.2 0.8 	 0.2 0.6 	 0.3 67,400 	 2.7
IL-2 0.0 0.0 0.0 0.0 0.0 13,063.5 	 1.1 0.2 	 0.03 0.1 	 0.03 63.4 	 1.8
IL-1 0.0 0.0 0.0 0.0 0.0 13.4 	 5.6 NA NA NA
IL-4 0.0 0.0 0.0 0.0 0.0 0.0 NA NA NA
IL-5 0.0 0.3 	 0.4 0.5 	 0.1 0.2 	 0.2 0.1 	 0.2 186.9 	 1.7 NA NA NA
IL-8 33.9 	 0.5 41.9 	 4.3 54.5 	 4.2 44.2 	 0.1 52.8 	 0.5 934.8 	 67.3 NA NA NA
IL-10 0.0 0.0 0.0 0.0 0.0 2,072.4 	 144.4 NA NA NA
IL-12p70 0.0 0.0 0.0 0.0 0.0 0.0 NA NA NA
IL-13 0.0 0.0 2.4 	 1.3 0.0 0.0 357.7 	 15.1 NA NA NA
a Resting CD4 T cells from healthy donors were stimulated for 48 h with the indicated stimulus. Data are the means of duplicate samples from 1 of 3 independent
experiments, all of which produced similar results. A 72-h treatment produced similar results.
b Resting CD4 T cells from healthy donors were stimulated for 24 h with the indicated stimulus. Induction is shown relative to unstimulated samples. Data are means
of triplicate samples from 1 of 2 independent experiments that produced similar results. NA, not applicable.
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the number of latency-reversing agents and illustrates the pos-
sibility of less-toxic approaches to reversing latency. Unlike
agents that cause global T cell activation, disulfiram is a rela-
tively nontoxic drug that has been taken daily by some patients
for decades. Although it is not yet clear that disulfiram can
reactivate latent HIV-1 in vivo, it is possible that this drug,
either alone or in combination with other agents, may be useful
in future eradication strategies.
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